Predictors of mortality in patients with acute myocardial infarction and cardiogenic shock

Circulation Journal

Volumn 69, Issue 1, 2005, Pages 83-88

  Katayama, Toshiro ^a,b   Nakashima, Hiroshi ^b   Takagi, Chisa ^b   Honda, Yukiharu ^b   Suzuki, Shin ^b   Yano, Katsusuke ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Cardiogenic shock; Myocardial infarction; Peptides; Prognosis

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; CREATINE KINASE; RENIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ARTICLE; CARDIOGENIC SHOCK; CAUSE OF DEATH; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE CONTRACTION; HEART VENTRICLE FIBRILLATION; HUMAN; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROTEIN BLOOD LEVEL; RELIABILITY; SURVIVAL;

ANGIOPLASTY, BALLOON; ASPIRIN; C-REACTIVE PROTEIN; CHOLESTEROL; ELECTROCARDIOGRAPHY; HORMONES; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; TICLOPIDINE; TREATMENT OUTCOME;

EID: 12344336194     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.83     Document Type: Article

References (31)

1. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. N Engl J Med 1985; 312: 932-936.
2. Kobayashi K, Kitamura K, Hirayama N, Date H, Kashiwagi T, Ikushima I, et al. Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 1996; 131: 676-680.
3. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.
4. Sigurdsson A, Held P, Swedberg K. Short-and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 1993; 126: 1068-1076.
5. Florence HS, Joachim S, Detlef GM, Mirle AK, Hugh S, Edward LB, et al. Measurement of regional wall motion from biplane contrast ventriculograms: A comparison of the 30 degree right anterior oblique projections in patients with acute myocardial infarction. Circulation 1986; 74: 796-804.
6. Rentrop KP, Cohen M, Blanko H, Phillips RA. Changes in the collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subject. J Am Coll Cardiol 1985; 5: 587-592.
7. Hasdai D, Topol EJ, Califf RM, Berger PB, Holmes DR Jr. Cardiogenic shock complicating acute coronary syndromes. Lancet 2000; 356: 749-756.
8. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, et al. One year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190-192.
9. Edep ME, Brown DL. Effect of early revascularization on mortality from cardiogenic shock complicating acute myocardial infarction in California. Am J Cardiol 2000; 85: 1185-1188.
10. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK Investigators (Should We Emergency Revascularize Occuluded Coronaries for Cardiogenic Shock). N Engl J Med 1999; 341: 625-634.
11. Menon V, Fincke R. Cardiogenic shock: A summary of the randomized SHOCK trial. Congest Heart Fail 2003; 9: 35-39.
12. Rauleau JL, de Champlain J, Klein M, Bichet D, Moye L, Packer M, et al. Activation of neurohumoral systems in post-infarction left ventricular dysfunction. J Am Coll Cardiol 1993; 22: 390-398.
13. Vaughan DE, Lamas GA, Pfeffer MA. Role of ventricular dysfunction in selective neurohumoral activation in the recovery phase of anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 529-532.
14. McAlpine HM, Cobbe SM. Neuro-endocrine changes in acute myocardial infarction. Am J Med 1988; 84: 61-66.
15. Takagi S, Sakuragi S, Baba T, Takaki H, Aihara N, Yasumura Y, et al. Predictors of left ventricular remodeling in patients with acute myocardial infarction participating in cardiac rehabilitation. Circ J 2004; 68: 214-219.
16. Kuga H, Ogawa K, Oida A, Taguchi I, Nakatsugawa M, Hoshi T, et al. Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. Circ J 2003; 67: 443-448.
17. Asakura M, Jiyoong K, Minamino T, Shintani Y, Asanuma H, Kitakaze M, and the J-WIND Investigators. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction. Circ J 2004; 68: 95-100.
18. Nishikimi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H. Cardioprotective effect of adrenomedullin in heart failure. Hypertens Res 2003; 26: 21-27.
19. Paul M, Ganten D. The molecular basis of cardiovascular hypertrophy: The role of the renin-angiotensin system. J Cardiovasc Pharmacol 1992; 19: 51-58.
20. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93: 1946-1950.
21. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.
22. Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immuno-reactive adrenomedullin in human tissue and plasma. FEBS Lett 1994; 338: 6-10.
23. Hirata Y, Hayakawa H, Suzuki Y, Suzuki E, Ikenouchi H, Kohmoto O, et al. Mechanism of adrenomedullin-induced vasodilation in the rat kidney. Hypertension 1995; 25: 790-795.
24. Lippton H, Chang JK, Hao Q, Summer W, Hyman AL. Adrenomedullin dilates the pulmonary vascular bed in vivo. J Appl Physiol 1994; 76: 2154-2156.
25. Miyao Y, Nishikimi T, Goto Y, Miyazaki S, Daikoku S, Morii I, et al. Increased plasma adrenomedullin levels in patients with acute myocardial infarction. Heart 1998; 79: 39-44.
26. Nagaya N, Nishikimi T, Uematsu M, Yoshitomi Y, Miyao Y, Miyazaki S, et al. Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. Heart 1999; 81: 483-487.
27. Nagaya N, Goto Y, Satoh T, Sumida H, Kolima S, Miyatake K, et al. Intravenous adrenomedullin in myocardial function and energy metabolism in patients after myocardial infarction. J Cardiovasc Pharmacol 2002; 39: 754-760.
28. Niu P, Shindo T, Iwata H, Limuro S, Takeda N, Zhang Y, et al. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation 2004; 109: 1789-1794.
29. Kawai J, Ando K, Tojo A, Shimosawa T, Takahashi K, Onozato M, et al. Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation 2004; 109: 1147-1153.
30. Okumura H, Nagaya N, Kangawa K. Adrenomedullin infusion during ischemia/reperfusion attenuates left ventricular remodeling and myocardial fibrosis in rats. Hypertension Res 2004; 26: 99-104.
31. Okumura H, Nagaya N, Itoh T, Okano I, Hino J, Mori K, et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 2004; 109: 242-248.